Under Dr. Holmlin's leadership, OpGen has garnered a plethora of accolades and milestones, including the validation of our optical genome mapping technology through extensive clinical research.

We are just too unique, powerful, useful and cost effective not to dominate broad and big areas of genetics research and diagnosis.

Strong partnerships: Bionano Genomics has established partnerships with leading research institutions and companies, which may help to drive demand for its technology.

It accepts various data types that enable clinical research laboratories to process CNVs, SNVs, AOH/LOH (and soon structural variants (SVs) from OGM)—all in a single place.

Even with ongoing operating losses, this cash pile should be sufficient to fuel ongoing research and innovation for a long time to come.

Praise for OGM from MD Anderson Cancer Center in the United States, one of if not the most prestigious cancer research centers in the U.S. All that and more.

But this looks good lets see if it fits the Bill for Cancer Research and Federal Funding Cancer Initiative.

$BIVI Biovie Pharmaceuticals $BIVI passes Zacks Equity Research's strict "Recent Price Strength screen", and comes out with glowing colors--and a prediction of further momentum for the stock in near term.

This provides the company with the resources to continue investing in research and development.

Congrats to New millionares Follow me for more awesome Research and financial advises.

Very pleased to see VP, research and development opened up his mouth, and get the message out to the investors, patients and hopefully tutes.

Well good news at ERQ3 when Petie will show that his exhaustive research showed that there is seasonality to sales and explains Q3 flat results.